Various tumor antigens—including VEGFR2, EGFR, HER2, MAGE, MUC1, FGFR, Flt4, and tumor-associated carbohydrate antigens—have been used in preclinical vaccine candidates [113]. This evidence concerns the gene MUC1 and neoplasm.